Skip to main content

Table 2 Effect of lactoferrin on the serum levels of SOD, IL-1β, -6, -18 and lipocalin in type 2 diabetic patients

From: Antidiabetic efficacy of lactoferrin in type 2 diabetic pediatrics; controlling impact on PPAR-γ, SIRT-1, and TLR4 downstream signaling pathway

Variables Diabetic patients (N = 30) Controls (N = 30)
Before lactoferrin After lactoferrin
SOD (U/mL) 143.6 ± 9.344a 175.9 ± 10.3b 222.5 ± 14.9
Interleukin-1β (pg/mL) 13.8 ± 1.8a 10.45 ± 1.37b 3.4 ± 0.8
Interleukin-6 (pg/mL) 16.78 ± 2a 11.5 ± 1.89b 4.9 ± 1.0
Interleukin-18 (pg/mL) 46.9 ± 6.4a 30.67 ± 4.15b 15.5 ± 2.87
Lipocalin 2 (pg/mL) 102.2 ± 11.7a 66.36 ± 13.2b 25.6 ± 3.9
  1. Values are means ± SDM
  2. SOD superoxide dismutase, IL interleukin
  3. aSignificant difference from normal group, at P ≤ 0.05
  4. bSignificant difference from diabetic patients before therapy, at P ≤ 0.05